{"entity":{"id":"mabquest","kind":"company","name":"MabQuest","aka":["MabQuest SA","MabQuest Therapeutics"],"tldr":"MabQuest is a Swiss company developing a new kind of anti-PD-1 antibody, a checkpoint inhibitor that releases a brake on the immune system, which binds PD-1 at a different site from current drugs. It is in an early trial in advanced solid tumours.","summary":"MabQuest SA (MabQuest Therapeutics) was founded in Lausanne, Switzerland, by Giuseppe Pantaleo and Craig Fenwick of Lausanne University Hospital, according to the company, and develops allosteric anti-PD-1 antibodies intended to work alongside conventional orthosteric anti-PD-1 therapies and other checkpoint inhibitors; it also lists interests in infectious disease and allergy. Its lead candidate is MAQ-001. Its first registered cancer trial, NCT06514651, a phase 1a/1b study of intravenous MAQ-001 alone and in combination immunotherapy, including with ipilimumab, in advanced solid tumours at French sites, was posted on ClinicalTrials.gov in July 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://mabquest.co/"},{"label":"About MabQuest","url":"https://mabquest.co/about-us"},{"label":"ClinicalTrials.gov: phase 1a/1b trial of MAQ-001 (NCT06514651)","url":"https://clinicaltrials.gov/study/NCT06514651"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["checkpoint-inhibitor","monoclonal-antibody"],"targets":["pd1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year and financing not stated on the pages read. That MAQ-001 is the allosteric anti-PD-1 antibody is inferred from the company's single described programme and the registry record. Read on 29 October 2026."],"hq":"Lausanne","country":"CH","companyType":"biotech","website":"https://mabquest.co/","stage":"startup","investors":[],"funding":[]},"route":"/companies/mabquest/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}]}}